Anti-inflammatory effect is an important property of niacin on atherosclerosis beyond its lipid-altering effects

Medical Hypotheses

Volumn 69, Issue 1, 2007, Pages 90-94

  Yu, Bi lian ^a   Zhao, Shui ping ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ANTILIPEMIC AGENT; LIPID; LIPOPROTEIN; NICOTINIC ACID;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CLINICAL EFFECTIVENESS; DYSLIPIDEMIA; HUMAN; IMMUNOCOMPETENT CELL; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; HUMANS; LIPIDS; MODELS, CARDIOVASCULAR; MODELS, IMMUNOLOGICAL; NIACIN; RECEPTORS, G-PROTEIN-COUPLED;

EID: 34247634533     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.11.026     Document Type: Article

References (39)

1. Meyers C.D., Kamanna V.S., and Kashyap M.L. Niacin therapy in atherosclerosis. Curr Opin Lipidol 15 (2004) 659-665
2. Malik S., and Kashyap M.L. Niacin, lipids, and heart disease. Curr Cardiol Rep 5 (2003) 470-476
3. Libby P., and Theroux P. Pathophysiology of coronary artery disease. Circulation 111 (2005) 3481-3488
4. Ross R. Atherosclerosis - an inflammatory disease. New Engl J Med 340 (1999) 115-126
5. Blake G.J., and Ridker P.M. Inflammatory bio-markers and cardiovascular risk prediction. J Int Med 252 (2002) 283-294
6. Kamanna V.S., and Kashyap M.L. Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep 2 (2000) 36-46
7. Zambon A., Hokanson J.E., Brown B.G., and Brunzell J.D. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation 99 (1999) 1959-1964
8. Superko H.R., and Krauss R.M. Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis 95 (1992) 69-76
9. McKenney J.M., McCormick L.S., Schaefer E.J., Black D.M., and Watkins M.L. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol 88 (2001) 270-274
10. Rosenson R.S., Otvos J.D., and Freedman D.S. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol 90 (2002) 89-94
11. Austin M.A. Epidemiology of hypertriglyceridemia and cardiovascular disease. Am J Cardiol 83 (1999) 13F-16F
12. Jin F.Y., Kamanna V.S., and Kashyap M.L. Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler Thromb Vasc Biol 19 (1999) 1051-1059
13. Sakai T., Kamanna V.S., and Kashyap M.L. Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol 21 (2001) 1783-1789
14. Van J.T., Pan J., Wasty T., Chan E., Wu X., and Charles M.A. Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus. Am J Cardiol 89 (2002) 1306-1308
15. Cheung M.C., Brown B.G., Wolf A.C., and Albers J.J. Altered particle size distribution of apolipoprotein A-I-containing lipoproteins in subjects with coronary artery disease. J Lipid Res 32 (1991) 383-394
16. Carlson L.A., Hamsten A., and Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Int Med 226 (1989) 271-276
17. Berg K., Dahlén G., Christophersen B., Cook T., Kjekshus J., and Pedersen T. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin Genet 52 (1997) 254-261
18. Wise A., Foord S.M., Fraser N.J., et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 278 (2003) 9869-9874
19. Soga T., Kamohara M., Takasaki J., et al. Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun 303 (2003) 364-369
20. Tunaru S., Kero J., Schaub A., et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its antilipolytic effect. Nat Med 9 (2003) 352-355
21. Pike N.B. Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid. J Clin Invest 115 (2005) 3400-3403
22. Zhang Y., Schmidt R.J., Foxworthy P., et al. Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A. Biochem Biophys Res Commun 334 (2005) 729-732
23. Sniderman A.D., and Cianflone K. Substrate delivery as a determinant of hepatic apoB secretion. Arterioscler Thromb 13 (1993) 629-636
24. Lewis G.F. Fatty acid regulation of very low density lipoprotein production. Curr Opin Lipidol 8 (1997) 146-153
25. Offermanns S. The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. Trends Pharmacol Sci 27 (2006) 384-390
26. Maciejewski-Lenoir D., Richman J.G., Hakak Y., Gaidarov I., Behan D.P., and Connolly D.T. Langerhans cells release prostaglandin D(2) in response to nicotinic acid. J Invest Dermatol 126 (2006) 2637-2646 Epub ahead of print
27. Benyo Z., Gille A., Kero J., et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest 115 (2005) 3634-3640
28. Schaub A., Futterer A., and Pfeffer K. PUMA-G, an IFN-gamma-inducible gene in macrophages is a novel member of the seven transmembrane spanning receptor superfamily. Eur J Immunol 31 (2001) 3714-3725
29. Du H.K., Wang S.X., Liu Y., and Zhang S.W. Effect of niacin on nitric oxide synthase expression in rat lung exposed to silica. Zhonghua Yu Fang Yi Xue Za Zhi 38 (2004) 186-189
30. Giri S.N. The combined treatment with taurine and niacin blocks the bleomycin-induced activation of nuclear factor-kappaB and lung fibrosis. Adv Exp Med Biol 526 (2003) 381-394
31. Ungerstedt J.S., Blomback M., and Soderstrom T. Nicotinamide is a potent inhibitor of proinflammatory cytokines. Clin Exp Immunol 131 (2003) 48-52
32. Blake G.J., and Ridker P.M. Inflammatory bio-markers and cardiovascular risk prediction. J Int Med 252 (2002) 283-294
33. Kashyap M.L., McGovern M.E., Berra K., et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation in patients with dyslipidemia. Am J Cardiol 89 (2002) 672-678
34. Grundy S.M., Vega G.L., McGovern M.E., et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial. Arch Int Med 162 (2002) 1568-1576
35. Kuvin J.T., Dave D.M., Sliney K.A., et al. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol 98 (2006) 743-745
36. Matsuzawa Y. Adiponectin: identification, physiology and clinical relevance in metabolic and vascular disease. Atheroscler Suppl 6 (2005) 7-14
37. Ouchi N., Kihara S., Funahashi T., Matsuzawa Y., and Walsh K. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 14 (2003) 561-566
38. Nedvidkova J., Smitka K., Kopsky V., and Hainer V. Adiponectin, an adipocyte-derived protein. Physiol Res 54 (2005) 133-140
39. Westphal S., Borucki K., Taneva E., Makarova R., and Luley C. Adipokines and treatment with niacin. Metabolism 55 (2006) 1283-1285